Core Viewpoint - Can-Fite BioPharma Ltd. is advancing its clinical pipeline, particularly focusing on the Phase IIa study of Namodenoson for advanced pancreatic cancer, which addresses a significant unmet medical need in this area [1][4]. Company Overview - Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company developing small molecule drugs for cancer and inflammatory diseases, with a focus on multi-billion dollar markets [5]. - The company's lead drug candidate, Piclidenoson, has recently reported topline results in a Phase 3 trial for psoriasis and is progressing to a pivotal Phase 3 trial [5]. - Namodenoson, another key drug, is being evaluated in multiple trials, including a Phase III trial for hepatocellular carcinoma (HCC) and a Phase 2a study for pancreatic cancer [5]. Clinical Trial Details - The Phase IIa clinical trial of Namodenoson is an open-label study involving patients with advanced pancreatic adenocarcinoma who have progressed after at least one prior therapy [2]. - The trial is assessing the safety, clinical activity, and pharmacokinetics of Namodenoson, administered at a dose of 25 mg twice daily in 28-day cycles, with approximately 20 evaluable patients expected to be enrolled [2]. - The trial is led by Prof. Salomon Stemmer, a prominent oncologist, and Namodenoson has received Orphan Drug Designation from the FDA for pancreatic cancer treatment [3]. Enrollment and Safety Profile - As of the latest update, 50% of the planned patient cohort has been enrolled, and Namodenoson has shown a favorable safety profile [4]. - The study aims to provide a novel therapeutic approach for patients with advanced pancreatic cancer who have exhausted standard treatment options [4].

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanomaFosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278Partnership leverages strategic relationships to enable research and development of innovative treatments to advance Teva's Pivot to Growth strategy TEL AVIV, Israel and SHANGHAI, June 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYS ...

Core Insights - Ascentage Pharma announced results from 13 studies of its key assets, including olverembatinib and APG-5918, at the 2025 European Hematology Association Annual Congress, highlighting their potential in treating unmet medical needs in cancers [1][2][3] Group 1: Olverembatinib - Olverembatinib, a third-generation tyrosine kinase inhibitor, showed significant clinical benefits in treating Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), with high complete remission (CR) and complete molecular response (CMR) rates [2] - In a study combining olverembatinib with blinatumomab, all patients achieved CR after one treatment cycle, with an overall survival (OS) rate of 100% and an event-free survival (EFS) rate of 91.6% at 18 months [6] - The combination of olverembatinib with the VP regimen resulted in a 100% overall response rate (ORR) and a 97.3% CR rate, indicating its effectiveness as a first-line therapy for adult patients with Ph+ ALL [11] Group 2: APG-5918 - APG-5918, an investigational EED inhibitor, demonstrated potent antitumor activity in preclinical studies for T-cell lymphoma, supporting its further clinical development [3][18] - The combination of APG-5918 with histone deacetylase inhibitor tucidinostat showed enhanced antitumor effects, indicating its potential as a therapeutic option [18] Group 3: Company Overview - Ascentage Pharma is focused on addressing unmet medical needs in cancers and has developed a pipeline of innovative drug candidates, including olverembatinib and APG-5918 [13] - The company is conducting global registrational Phase III trials for olverembatinib in various indications, including newly diagnosed Ph+ ALL and GIST patients [14]

Yep, that's me. Yeah. Yeah.Budding artist. They call me smock face. But uh you know there's this really great saying from from Picasso who uh said that you know all children are born artists and the problem is remaining an artist as we grow up and actually you know it might surprise you to think that being a cancer researcher is pretty similar a budding scientist artist here.After all, I mean, kids are naturally very inquisitive. They just have this ability to pick out symmetry and patterns from the environ ...

Core Insights - Processa Pharmaceuticals, Inc. is participating in the 2025 BIO International Convention to showcase its Next Generation Cancer (NGC) therapies [1][4] - The company will provide updates on its strategic direction and clinical progress, particularly focusing on its lead asset NGC-Cap, which is in a Phase 2 trial for metastatic breast cancer [2][3] - The CEO emphasized the opportunity to engage with potential partners committed to developing safer and more effective cancer treatments [3] Company Overview - Processa Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing NGC drugs that enhance safety and efficacy [5] - The NGC drugs are modifications of existing FDA-approved oncology therapies, aiming to alter metabolism and distribution while maintaining cancer cell-killing mechanisms [5] - The company's strategy combines a novel oncology pipeline with proven active molecules and a Regulatory Science Approach to improve therapy options for cancer patients [5]

Core Insights - Revumenib, in combination with venetoclax and azacitidine, shows promising clinical activity in older patients with newly diagnosed mNPM1 and KMT2Ar AML, achieving a 67% complete remission (CR) rate and an 88% overall response rate (ORR) [1][2][6] - The ongoing Phase 3 EVOLVE-2 trial is evaluating the efficacy of this combination in newly diagnosed mNPM1 AML patients who are unfit for intensive chemotherapy [1][2] Group 1: Clinical Trial Results - The BEAT AML trial reported a 67% CR rate (29 out of 43 patients) and an 88% ORR (38 out of 43 patients) among newly diagnosed older adults with mNPM1 or KMT2Ar AML [1][6] - Among 37 patients assessed for measurable residual disease (MRD), 100% were found to be MRD negative [6] - The median duration of composite complete remission (CRc) was 12.0 months [6] Group 2: Patient Demographics and Safety - As of September 2024, 43 patients were enrolled, with 79% having mNPM1 AML and 21% KMT2Ar AML; the median age was 70 years [4][5] - Revumenib was generally well tolerated, with common non-hematologic treatment-emergent adverse events including nausea (60%), constipation (53%), and QTc prolongation (44%) [5][6] Group 3: Comparative Outcomes - The observed median overall survival (OS) was 15.5 months, with a CRc rate of 77% in mNPM1 patients and 89% in KMT2Ar patients [7][8] - Historical data indicated lower CRc rates and median OS for patients treated with venetoclax and azacitidine alone, highlighting the potential of revumenib in improving outcomes [8] Group 4: Future Developments - Revumenib is being developed for the treatment of relapsed or refractory AML with mNPM1 mutations, with a supplemental NDA submitted in April 2025 [10] - The company is conducting multiple trials of revumenib in combination with standard-of-care agents across various treatment settings [10][25]

Crispr Technology & Applications - Crispr 基因编辑技术能够对患者的 DNA 进行精确编辑，从而识别新的治疗靶点并纠正某些疾病，扩大可治疗疾病的范围 [2] - Crispr 技术与 AI 结合，加速识别靶点和疗法，从而加快新疗法上市的速度 [3] - 癌症，尤其是无法以其他方式治疗的儿童疾病和罕见癌症，可能是 Crispr 技术首先产生影响的领域 [5] Regulatory Landscape - FDA 对新的治疗方法和技术平台持支持态度，并倾向于快速批准 [5] - 美国卫生与公众服务部 (HHS) 部长承诺支持细胞和基因治疗领域，这对行业来说是一个巨大的推动力 [7] - 众议院拨款委员会也表达了对细胞和基因治疗领域的支持，释放了积极信号 [7] Manufacturing & Supply Chain - 该公司主要在美国本土进行生产，对进口尤其是来自中国的依赖程度不高 [9] - 公司在马萨诸塞州进行生产，并在匹兹堡进行扩张 [9] - 匹兹堡的团队致力于支持当地学校的 STEM (科学、技术、工程和数学) 项目 [9]

Company Overview - Medicus Pharma Ltd. is a biotechnology company focused on developing novel therapeutics, particularly in the field of oncology [6][7] - The company's lead asset, SkinJect Inc., is developing a treatment for non-melanoma skin cancer using a patented dissolvable doxorubicin-containing microneedle array (D-MNA) [2][6] Clinical Trials - Medicus is conducting a Phase 2 clinical study (SKNJCT-003) across nine clinical sites in the United States, which began randomizing patients in August 2024 [3] - An interim analysis in March 2025 showed over 60% clinical clearance after more than 50% of the targeted 60 patients were randomized [3] - The investigational review board increased the number of participants in SKNJCT-003 to 90 subjects and expanded clinical trial sites to Europe [3] - A separate clinical study (SKNJCT-004) is underway in the UAE, aiming to randomize 36 patients across four sites [4] Acquisition Plans - In April 2025, Medicus entered into a binding letter of intent to acquire Antev Ltd., a UK-based biotech company developing Teverelix for advanced prostate cancer patients [5][8] - The acquisition is subject to due diligence, negotiation of definitive agreements, and regulatory approvals [8] Upcoming Events - Dr. Raza Bokhari, Executive Chairman and CEO of Medicus, will present corporate updates at the 2025 Bio International Convention on June 17, 2025 [1][2]

Core Insights - The KOMET-007 trial demonstrated encouraging clinical activity for ziftomenib in combination with 7+3 for newly diagnosed NPM1-m and KMT2A-r AML patients, showing high rates of complete remission and minimal residual disease negativity [1][2][4] Group 1: Clinical Data - In the KOMET-007 trial, 93% (41/44) of NPM1-m patients and 89% (24/27) of KMT2A-r patients achieved complete remission composite (CRc) [1] - Among responding patients, 71% (24/34) of NPM1-m and 88% (14/16) of KMT2A-r patients achieved measurable residual disease (MRD) negativity [1] - The median follow-up times were 24.9 weeks for NPM1-m patients and 15.7 weeks for KMT2A-r patients, with 96% (47/49) of NPM1-m and 88% (29/33) of KMT2A-r patients remaining alive [3] Group 2: Safety and Tolerability - The safety profile of ziftomenib was consistent with previous data, with Grade 3 adverse events occurring in over 10% of patients, including febrile neutropenia (15%) and decreased platelet count (15%) [4] - No dose-limiting toxicities or additive myelosuppression were observed, indicating a favorable safety profile for ziftomenib [4] Group 3: Future Developments - Kura Oncology plans to initiate the KOMET-017-IC and NIC Phase 3 studies in the second half of 2025 to further evaluate ziftomenib's efficacy in AML treatment [1][5] - A virtual investor event is scheduled for June 18, 2025, to discuss the results and broader development plans for ziftomenib [6] Group 4: Company Background - Kura Oncology is focused on developing precision medicines for cancer, with ziftomenib being the first investigational therapy to receive Breakthrough Therapy Designation from the FDA for R/R NPM1-m AML [7] - Kyowa Kirin, a partner in the development of ziftomenib, has a long history in drug discovery and biotechnology innovation, aiming to address high unmet medical needs [9]

Core Insights - Compugen Ltd. is a clinical-stage cancer immunotherapy company that utilizes AI/ML driven predictive computational research to enhance understanding of complex cancer biology [1][2]. Group 1: Conference Presentations - Compugen will present at the 2025 Annual Congress of the European Association for Cancer Research in Lisbon, Portugal, from June 16-19, with a poster titled "Prediction of immune evasion and immunotherapy resistance mechanisms associated with distinct TNBC subtypes" [2]. - Another presentation will occur at the International Society for Computational Biology and European Conference on Computational Biology in Liverpool, UK, from July 20-24, featuring a poster titled "Computational prediction of TNBC tumor subtypes from an integrative single cell atlas elucidates immune evasion and immunotherapy resistance mechanisms" [2]. Group 2: Company Overview - Compugen employs a predictive computational discovery platform (UnigenTM) to identify new drug targets and biological pathways for cancer immunotherapy development [3]. - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3]. - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3]. - GS-0321, a high affinity anti-IL-18 binding protein antibody, is also in Phase 1 development and licensed to Gilead [3]. - Compugen's therapeutic pipeline includes early-stage immuno-oncology programs aimed at enhancing anti-cancer immunity [3].